Managing advanced prostate cancer with Viadur (leuprolide acetate implant).

Journal Article (Review)

Viadur (leuprolide acetate implant), providing a sustained release of drug over a 12-month duration, decreases serum testosterone in advanced prostate cancer patients, providing long-term, palliative medical hormonal therapy. Clinical experience suggests Viadur implants are safe, effective, and generally well tolerated. The continuous drug delivery provided by Viadur ensures compliance. The Viadur implants was designed to be maintenance-free, thereby allowing nurses and other health professionals to focus on other patient needs, such as followup visits and diagnostic tests. Viadur is one aspect of a comprehensive approach to patient management, which also includes regular followup for prostate-specific antigen testing, digital rectal examination, and other tests throughout the 1-year therapy.

Full Text

Duke Authors

Cited Authors

  • Moul, JW; Civitelli, K

Published Date

  • December 2001

Published In

Volume / Issue

  • 21 / 6

Start / End Page

  • 385 - 394

PubMed ID

  • 11998504

International Standard Serial Number (ISSN)

  • 1053-816X

Language

  • eng

Conference Location

  • United States